ArticleInflammatory intestinal diseases2017

The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.

Linda Russi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.